Daniel Woolson, who serves as President of ICU Medical Inc. (NASDAQ:ICUI), recently disposed of a substantial holding of the company's common stock. On May 22, 2026, Mr. Woolson sold 2,123 shares of common stock, totaling an approximate value of $280,684.
The details provided in the filing indicate that these sales were executed at a weighted average price of $132.2114 per share. Furthermore, the transactions took place within a relatively tight pricing band, specifically between $132.03 and $132.33 per share, inclusive.
Following this disposition of shares, Mr. Woolson's direct personal holding in ICU Medical common stock was reduced to 22,479 shares.
Company Valuation and Market Metrics
As of the reporting period, the stock for ICU Medical trades at $133.34 per share. The company maintains a current market capitalization estimated at $3.34 billion. Despite the recent executive selling activity, external analysis suggests that ICU Medical may be trading below its intrinsic value. Specifically, according to InvestingPro analysis, the medical device maker appears undervalued at current price levels.
The valuation metrics also point toward potential growth opportunities. The company currently reports a PEG ratio of 0.47, and supplemental information from InvestingPro Tips forecasts that net income is expected to demonstrate growth throughout this year.
For investors seeking more detailed insights into the equity, comprehensive Pro Research Reports are available, covering not only ICUI but also over 1,400 other US equities.
Strong Financial Performance and Governance Changes
In separate corporate news, ICU Medical Inc. released its financial results for the first quarter of 2026. These earnings demonstrated a robust performance, surpassing market expectations across key metrics.
The company reported an earnings per share (EPS) of $1.97 for the quarter. This figure exceeded the forecasted EPS of $1.76. Furthermore, ICU Medical's revenue also surpassed projections, reaching $530.22 million when analysts had anticipated $522.38 million. These combined financial results signal a strong operational period for the medical device manufacturer.
In addition to its financial achievements, ICU Medical announced that shareholders approved several significant amendments to its Amended and Restated Certificate of Incorporation. These amendments involve structural changes to the company's governance framework. Notably, certain supermajority voting requirements were eliminated, opting instead for a simple majority voting standard. The shareholder vote also sanctioned provisions enabling stockholders who possess at least 25% voting power to convene a special meeting.
These Charter Amendments officially became effective upon their formal filing with the Secretary of State of Delaware.
Disclaimer: This analysis is based strictly on disclosed filings and public financial data.